Target-based drug discovery is the dominant paradigm of drug discovery; however, a
comprehensive evaluation of its real-world efficiency is lacking. Here, a manual systematic …

The β3‐adrenoceptor was initially an attractive target for several pharmaceutical companies
due to its high expression in rodent adipose tissue, where its activation resulted in …

β3‐Adrenoceptor agonists are used in the treatment of overactive bladder syndrome.
Although the relaxant response to adrenergic stimulation in human detrusor smooth muscle …

Aim To review evidence for novel drug targets that can manage overactive bladder (OAB)
symptoms. Methods A think tank considered evidence from the literature and their own …

Rett Syndrome is an X-linked neurodevelopmental disorder (RTT; OMIM# 312750)
associated to MECP2 mutations. MeCP2 dysfunction is seen as one cause for the …

Overactive bladder (OAB) syndrome is a prevalent condition of the lower urinary tract that
causes symptoms, such as urinary frequency, urinary urgency, urge incontinence, and …

A specific type of beta-adrenergic receptor was discovered in the decade of 1980s and
subsequently recognized as a new type of beta-adrenergic receptor, called beta3 …

Background and Purpose The mechanism by which β3 receptor agonists (eg mirabegron)
control bladder overactivity may involve adenosine release from human and rat detrusor …

Parasympathetic nerve-mediated contractions of detrusor smooth muscle are generated by
ATP and acetylcholine (ACh) release from efferent nerve terminals. In humans, ACh is …

Motility of detrusor smooth muscle includes adrenergic relaxation and cholinergic
contraction. Since the latter may be deregulated in overactive bladder (OAB) …